At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 18 enrolled
Drug / intervention
Hydroxychloroquine +3 moredrug
Likely dose
Hydroxychloroquine 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting
In Brief
A Phase 4 clinical trial evaluating Hydroxychloroquine, Azithromycin, and 2 other interventions for COVID-19. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedMay 2020
Primary CompletionSep 2020
TodayJul 2026
First PostedMay 1, 2020
Enrollment StartApr 28, 2020
Primary CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.2 years ago
Interventions
Hydroxychloroquinedrug
Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
Azithromycindrug
Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
Zinc Sulfatedrug
Zinc sulfate 220mg once daily for 5 days
Doxycyclinedrug
Doxycycline 200 mg once daily for 5 days